Greenyn Biotechnology Co., Ltd.

As of June 30, 2026, Greenyn Biotechnology Co., Ltd. carries a market capitalization of 1.80B, placing it among publicly traded companies globally. Its enterprise value stands at 1.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Greenyn Biotechnology Co., Ltd.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Greenyn Biotechnology Co., Ltd. has 27.07M shares outstanding.

As of June 30, 2026, Greenyn Biotechnology Co., Ltd. trades at a trailing price-to-earnings ratio of 14.17. The price-to-sales ratio is 2.08, and the price-to-book ratio stands at 1.96.

As of June 30, 2026, Greenyn Biotechnology Co., Ltd. trades at an EV/EBITDA multiple of 9.24 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.63 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.84B versus a market cap of 1.80B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Greenyn Biotechnology Co., Ltd. maintains a current ratio of 4.78, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 132.63, indicating elevated leverage, while an interest coverage ratio of 12.84 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Greenyn Biotechnology Co., Ltd. posted a return on equity (ROE) of 14.03, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.49 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.90, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.38, useful for judging operating efficiency across full business cycles. The company generates approximately 6.57M in revenue per employee across its workforce of 132.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.49 indicates how many times Greenyn Biotechnology Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Greenyn Biotechnology Co., Ltd. recorded 34.92M in income tax expense. That works out to an effective tax rate of 21.53, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 162.16M, leaving 127.24M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Greenyn Biotechnology Co., Ltd.'s stock has declined approximately 21.54% over the past 52 weeks. The 50-day moving average sits at 58.16, while the 200-day moving average is 66.66.

Over the twelve months ended June 30, 2026, Greenyn Biotechnology Co., Ltd. generated 867.63M in revenue and converted that into 127.24M in net income, yielding earnings per share of 3.98. EBITDA reached 198.74M, while operating income came in at 157.77M.

As of June 30, 2026, Greenyn Biotechnology Co., Ltd. holds 1.18B in cash and equivalents against 1.22B in total debt, resulting in a net debt position of 519.52M. Total book value stands at 917.96M, with working capital of 1.21B providing operational flexibility.

Greenyn Biotechnology Co., Ltd. produced 130.08M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -463.81M in capital expenditures, free cash flow totaled -333.73M - equivalent to -12.32 per share.

Over the twelve months ended June 30, 2026, Greenyn Biotechnology Co., Ltd. posted a gross margin of 48.04, reflecting its pricing power and cost economics. The operating margin of 18.18 and net profit margin of 14.67 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Greenyn Biotechnology Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -15.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -27.70, meaning Greenyn Biotechnology Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Greenyn Biotechnology Co., Ltd. has an Altman Z-Score of 2.01, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.